Overview

Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis

Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
0
Participant gender:
Female
Summary
This protocol is designed to study the effect and safety of 2 low-dose regimens of conjugated estrogen cream (PVC) given vaginally in postmenopausal women with atrophic vaginitis.
Phase:
Phase 3
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Estrogens
Estrogens, Conjugated (USP)
Criteria
Inclusion Criteria:

Generally healthy postmenopausal women with symptoms of atrophic vaginitis including
vaginal dryness, vaginal itching, vaginal burning, and/or painful intercourse.

The subject must have a clinical diagnosis of atrophic vaginitis and an intact uterus.

Exclusion Criteria:

Women who do not have a clinical diagnosis of atrophic vaginitis.